Mauna Kea Technologies Publishes Landmark Review on Cellvizio’s Accuracy in Upper GI Cancer
Mauna Kea Technologies announced the publication of an independent systematic review and meta-analysis on the diagnostic accuracy of its Cellvizio platform in upper gastrointestinal cancer. This study, conducted by Korea’s national health technology assessment agency, reinforces the clinical impact of probe-based confocal laser endomicroscopy (pCLE).
PARIS & BOSTON–(BUSINESS WIRE)–Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the publication of a landmark independent systematic review and meta-analysis of probe-based confocal laser endomicroscopy (pCLE) in upper gastrointestinal cancer, conducted and funded by Korea’s national health technology assessment agency. Published as an original